Background: Elevated homocysteine levels are associated with increased blood coagulation
and platelet activity and may modulate the response to antiplatelet therapies. We aimed to …

Objectives: To investigate the relationship of homocysteine levels with the efficacy and
safety of dual antiplatelet therapy in female and male patients. Approach and Results: The …

Background Previous ischemic stroke is a predictor of recurrent ischemic stroke after an
acute myocardial infarction (AMI). Dual antiplatelet therapy, including a P2Y12-inhibitor, is …

Introduction: Currently, it is still controversial to treat stroke with ticagrelor alone. The
purpose of our study was to systematically review and analyze the efficacy and safety of …

Introduction: Currently, it is still controversial to treat stroke with ticagrelor alone. The
purpose of our study was to systematically review and analyze the efficacy and safety of …

In the Acute Stroke or TIA Treated with Aspirin or Ticagrelor and Patient Outcomes
(SOCRATES) trial, ticagrelor was not superior to aspirin in reducing the risk of the composite …

Background and Purpose—Guidelines recommend dual antiplatelet treatment with
ticagrelor instead of clopidogrel after acute myocardial infarction. Ticagrelor increases major …

Introduction: While various antiplatelet regimens are currently available for secondary
prevention after ischemic stroke, data comparing their efficacy and safety are scarce. We …

Background and purpose It remains unclear whether smoking status has an impact on
platelet reactivity and clinical outcomes of ticagrelor versus clopidogrel in patients with acute …

Recurrence risk after transient ischemic attack (TIA) or ischemic stroke (IS) ranges from 5 to
20% per year [1–3]. The risk is highest immediately after the first event [4–6]. Numerous trials …